The recent move to introduce an “Amazon-style” prescription tracking in the NHS App is a crucial first step. People want ...

Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn't require an ...

In a new study, the large-language model (LLM) ChatGPT was able to reduce the time needed to review whether a patient is suitable for a clinical trial and delivered big reductions – from an average of ...

From trade associations to medtech innovators and biotech start-ups, here’s a comprehensive look at the latest boardroom ...

"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their ...

Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution ...

In the next part of his series on the history of the pharmaceutical industry, Robin Walsh looks at the biggest company of them all – Pfizer. Pfizer was founded in 1849 by two recent German ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.

Read pharmaphorum's vision and mission statement and learn about our world-class editorial team.

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA approval that sets up a launch before the end of this year. Widaplik ...

The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug in the ...